EUCTR2004-004728-11-DK进行中（未招募）不适用
A Multicenter, Randomized, Controlled, Observer-Blinded, Dose-Response Study to Evaluate The Efficacy in Tracheal Intubation and Safety of Gantacurium Chloride for Injection in Healthy Adult Patients Undergoing Surgery with General Anesthesia.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A patient will be eligible for inclusion in this study only if all of the following criteria are met:
- •1. Male or female between 18 and 65 years of age scheduled for low- or moderate-risk surgical procedure requiring tracheal intubation
- •2. Female patients must not be of child-bearing potential. Females must meet one of the following criteria:
- •Be postmenopausal;
- •Have undergone prior tubal ligation or hysterectomy; or
- •Be scheduled for hysterectomy as the surgical procedure for this study
- •3. ASA Physical Status Classification 1 or 2 ( refer to Appendix C)
- •4. Weight within 30% of ideal body weight (refer to Appendix D)
- •5. Able to read and to comprehend information about the study design and procedure; willingness to participate in this study as evidenced by a signed and dated written Informed Consent Form
- •6. In good physical and mental health as determined by the following procedures/evaluations (completed within 14 days prior to the Induction Phase [scheduled surgical procedure]):
- •A complete medical history
- •A complete physical examination
- •A standard 12-lead ECG and rhythm strip
- •Measurement of vital signs, including BP (supine), HR/pulse (supine), respiration rate and temperature
- •Urinalysis and clinical laboratory tests (in accordance with local practice for preoperative assessment)
- •[Note: The investigator may assess eligibility for the study based on the results of laboratory tests on blood and urine samples taken for routine pre-operative assessment up to 2 weeks prior to the Induction Phase of the study and analyzed at a local laboratory]
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A patient will not be eligible for inclusion in this study if any of the following criteria are met:
- •1. Evidence of clinically significant cardiovascular, neuromuscular, neurological, psychiatric, renal, hepatic or pulmonary disease (including asthma), or impairment of function (as judged by the investigator)
- •2. Personal or family history of unusual sensitivity to NMBs or other agents used in surgical anesthesia
- •3. Anatomical characteristics recognized as being associated with difficult intubation conditions, even in the presence of complete jaw and vocal cord relaxation
- •4. History or evidence of vocal cord polyps and/or paralysis
- •5. History or evidence of narrow angle glaucoma
- •6. Personal or family history of malignant hyperthermia
- •7. History of major thermal injury that required hospitalization
- •8. Presence of genetically determined disorders of plasma cholinesterase, as determined by medical history
- •9. History or current evidence of abuse of any drug substance, licit or illicit (including alcohol)
- •10. Exposure to any of the following agents within 48 hours prior to the Induction Phase of the study, or, if expected to be administered within the first 15 minutes after administration of Study Treatment: antibiotics (except penicillins, cephalosporins, and tetracyclines), i.v. lidocaine (except i.v. lidocaine administered in conjunction with propofol to reduce local irritation), quinidine, trimetaphan, or dexamethasone.
- •11. Exposure to any of the following agents within 7 days prior to the Induction Phase of the study: tricyclic antidepressants, phenothiazines, anticonvulsants, antihistamines (H1 - or H2 -receptor antagonists), antihypertensives, antiarrhythmics (including procainamide), beta blockers (including propranolol, calcium channel blockers), diuretics (including furosemide, thiazides, mannitol and acetazolamide), potent narcotics (including, but not limited to, oxycodone, methadone, morphine, buprenorphine, hydromorphone), and magnesium or lithium salts. Note: weak opioids including, but not limited to, propoxyphene, tramadol, hydrocodone, codeine, meperidine and tilidine are not reasons for exclusion provided no changes in daily dosage have occurred within 3 days prior to the Induction Phase of the study.
- •12. Exposure to monoamine oxidase inhibitors within 14 days prior to the Induction Phase of the study.
- •13. Exposure to anticholinesterase or cholinomimetic agents within 30 days prior to the Induction Phase
- •14. Previous entry into this or any other study of Gantacurium Chloride for Injection, or participation in any other investigational drug, biologic, or medical device study within 30 days prior to the Induction Phase
- •15. Pregnant (positive pregnancy test during Screening) or breastfeeding/donating breast milk
- •16. Any other condition that, in the opinion of the investigator, would jeopardize the safety or rights of a subject participating in the trial or would render the subject unable to comply with the protocol
研究者
相似试验
进行中（未招募）
不适用
A Multicenter, Randomized, Controlled, Observer-Blinded, Dose-Response Study to Evaluate The Efficacy in Tracheal Intubation and Safety of Gantacurium Chloride for Injection in Healthy Adult Patients Undergoing Surgery with General Anesthesia.Adjunct to anesthesia to facilitate tracheal intubation (non-depolarizing neuromuscular blocking agent)EUCTR2004-004728-11-DEAvera Pharmaceuticals Inc.230
进行中（未招募）
1 期
A Multicenter, Randomized, Controlled, Observer-Blinded, Dose-Response Study to Evaluate The Efficacy in Tracheal Intubation and Safety of Gantacurium Chloride for Injection in Healthy Adult Patients Undergoing Surgery with General Anesthesia.Adjunct to anesthesia to facilitate tracheal intubation (non-depolarizing neuromuscular blocking agent)EUCTR2004-004728-11-GBAvera Pharmaceuticals Inc.250
已完成
1 期
A Multicentre, Randomised, Controlled, Observer-Blind Study to Evaluate Safety and Duration in Stomach of Modified Release Prototype Capsules in Healthy AdultsACTRN12618000991213yndra Australia Pty Ltd.40
尚未招募
1 期
A randomized, blinded study, using multiple increasing doses of RO5310074, studying the effects of RO5310074 in patients with psoriatic arthritisPsoriatic arthritisInflammatory and Immune System - Rheumatoid arthritisACTRN12610000694011Roche Products Pty Ltd21
进行中（未招募）
不适用
A single-center, randomized, controlled, observer-blind, phase IV study to develop the atopic localized eczema regression test (ALERT) using marketed topical corticosteroid formulations of different strength and the calcineurin inhibitors pimecrolimus (Elidel®) in patients with a pre-disposition for atopic dermatitis - Atopic localized eczema regression test (ALERT)Patients with a pre-disposition for Atopic DermatitisEUCTR2009-012194-35-DEbioskin GmbH